Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials

Alexander D. Sherry, Pavlos Msaouel, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Cullen M. Taniguchi, Clifton D. Fuller, Bruce D. Minsky, Ethan B. Ludmir

Abstract

Missing visual elements (MVE) in Kaplan-Meier (KM) curves can misrepresent data, preclude curve reconstruction, and hamper transparency. This study evaluated KM plots of phase III oncology trials. MVE were defined as an incomplete y-axis range or missing number at risk table in a KM curve. Surrogate endpoint KM curves were additionally evaluated for complete interpretability, defined by (1) reporting the number of censored patients and (2) correspondence of the disease assessment interval with the number at risk interval. Among 641 trials enrolling 518 235 patients, 116 trials (18%) had MVE in KM curves. Industry sponsorship, larger trials, and more recently published trials were correlated with lower odds of MVE. Only 3% of trials (15 of 574) published surrogate endpoint KM plots with complete interpretability. Improvements in the quality of KM curves of phase III oncology trials, particularly for surrogate endpoints, are needed for greater interpretability, reproducibility, and transparency in oncology research.

Locations

• The Oncologist - View - PDF
• PubMed Central - View
• PubMed - View